Cargando…
Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C
INTRODUCTION: Hepatitis C virus (HCV) infection is one of the principle causes of chronic liver disease. Successful treatment significantly decreases the risk of hepatic morbidity and mortality. Current standard of care achieves sustained virologic response (SVR) rates of 40–80%; however, the HCV th...
Autores principales: | McEwan, Phil, Ward, Thomas, Bennett, Hayley, Kalsekar, Anupama, Webster, Samantha, Brenner, Michael, Yuan, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311930/ https://www.ncbi.nlm.nih.gov/pubmed/25635922 http://dx.doi.org/10.1371/journal.pone.0117334 |
Ejemplares similares
-
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017) -
Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections
por: Bennett, Hayley, et al.
Publicado: (2015) -
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies
por: Chawla, Anita J, et al.
Publicado: (2014) -
Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea
por: Kim, Do Young, et al.
Publicado: (2017) -
The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
por: McEwan, Phil, et al.
Publicado: (2016)